Nasal stem cell exosomes for autoimmune encephalitis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether an experimental treatment using tiny particles from stem cells (called exosomes) given through the nose can help people with autoimmune encephalitis. It is for adults who were recently diagnosed and have specific antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have been diagnosed with autoimmune encephalitis within the past 3 months, and have certain antibodies (anti-NMDAR or anti-LGI1) in your blood or spinal fluid.
- You need to have some disability from the disease, as measured by a score called mRS (modified Rankin Scale) of 2 or higher.
- You cannot have serious health problems like severe heart, liver, or kidney disease, or certain infections.
- You must agree to use effective birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
This study is for people with autoimmune encephalitis, a condition where the immune system attacks the brain. It aims to collect information about this disease to learn more about it and how to treat it.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
This study tests a new drug called CTA313 for people with certain autoimmune diseases like lupus, multiple sclerosis, or autoimmune encephalitis. It aims to see if the drug is safe and effective for these conditions.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.